High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Recruiting

Phase 3

GabapentinHigh-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT06992427

Conditions

Head and Neck Squamous Cell Carcinoma

Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8

Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8

Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8

Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Gabapentin

Placebo

Chemotheraphy

Radiation Therapy

Analgesic Agent

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2025-10-08.